Pharmacist clears up confusion about remdesivir

Depending on which day you checked the news recently, the antiviral drug remdesivir is not showing impressive results in COVID-19 patients or is the godsend so many health care providers have been wishing for to improve treatment results.

Leaks from a Chinese study that was eventually published by the peer-reviewed academic journal Lancet didn’t show a statistically significant difference in giving patients remdesivir versus a placebo. More recently, the National Institute of Allergy and Infectious Diseases released data that appears to show remdesivir does shorten patients’ recovery time by four days.

Chris Bland, an infectious diseases specialist and clinical associate professor of pharmacy at the University of Georgia, cuts through the academic red tape to tell you what you need to know about the latest COVID-19 prospect.

Read the story by Leigh Beeson in UGA Today.

Connect with the UGA College of Pharmacy